Armata Pharmaceuticals (ARMP) Retained Earnings (2013 - 2026)

Armata Pharmaceuticals has disclosed Retained Earnings across 14 years of filings, most recently posting -$616.9 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$616.9 million, down 84.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$616.9 million (down 84.53% YoY), and the FY2025 annual result was -$501.5 million, down 53.03% from the prior year.
• Retained Earnings came in at -$616.9 million for Q1 2026 at Armata Pharmaceuticals, down from -$501.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$211.6 million in Q1 2022 to a low of -$616.9 million in Q1 2026.
• The 5-year median for Retained Earnings is -$324.9 million (2024), against an average of -$324.1 million.
• Across the five-year window, Retained Earnings slipped 0.14% in 2025 and slumped 84.53% in 2026, its largest moves.
• Armata Pharmaceuticals' Retained Earnings stood at -$239.8 million in 2022, then decreased by 28.8% to -$308.8 million in 2023, then decreased by 6.13% to -$327.7 million in 2024, then sank by 53.03% to -$501.5 million in 2025, then fell by 23.0% to -$616.9 million in 2026.
• The last three Retained Earnings figures came in at -$616.9 million (Q1 2026), -$501.5 million (Q4 2025), and -$377.2 million (Q3 2025), per Business Quant data.